Browsing by Author "Sankha S. Chakrabarti"

Now showing 1 - 10 of 10

Cerebrospinal Fluid Protein Profiles in Alzheimer's Dementia Patients: A Bioinformatic Approach
(Wolters Kluwer Medknow Publications, 2023) Anamika Misra; Sankha S. Chakrabarti; Indrajeet S. Gambhir; Meghraj S. Baghel; Yugendra R. Patil
[No abstract available]
Cross-immunity and trained immunity in explaining variable COVID-19 mortality—Guidance for future pandemics
(John Wiley and Sons Inc, 2021) Sasanka Chakrabarti; Sankha S. Chakrabarti; Upinder Kaur; Bimal K. Agrawal; Upasana Ganguly; Kunlin Jin
[No abstract available]
Delayed neuroleptic malignant syndrome associated with the use of low dose risperidone in conjunction with cholinergic drugsthe dangers of polypharmacy in the elderly
(Bentham Science Publishers B.V., 2018) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir; Deepak K. Gautam
Background: Neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction with systemic manifestations like fever, rigidity, altered sensorium and autonomic disturbances. The syndrome is often seen within days to weeks in patients being treated with antipsychotics. Though reported with the use of atypical antipsychotics, it is relatively uncommon to occur if patient is on a stable dose of antipsychotic for a long time. Objective: Here we report a case of delayed NMS with risperidone use at the lowest recommended dose. Method: Review of probable etiology including drug review was performed in a 60 year hypertensive female presenting with progressive limitation of movements and rigidity in upper and lower limbs along with bilateral hand tremors, fever, poor speech, difficulty in swallowing, agitated behavior, urinary incontinence and altered mental status. Results: NMS occurred in the patient of schizophrenia on the lowest possible therapeutic dose of risperidone of 0.5 mg/day, after 14 years of therapy. The case highlights the possible drug interaction between risperidone and cholinergic drugs resulting in the catastrophe. (Videos before and after therapy are part of submission) Conclusion: Physicians should be vigilant of the risk of NMS with atypical antipsychotics like risperidone particularly when administered along with cholinergic drugs. NMS can occur even after long term use of a stable dose of antipsychotic. Cholinergic drugs like donepezil, citicoline and piracetam should be used with caution in patients who are already on antipsychotics and if needed should be added one by one. © 2018 Bentham Science Publishers.
Identifying the mechanisms of α-synuclein-mediated cytotoxicity in Parkinson's disease: New insights from a bioinformatics-based approach
(Future Medicine Ltd., 2020) Sankha S. Chakrabarti; Venkatadri S. Sunder; Upinder Kaur; Sapna Bala; Priyanka Sharma; Manjari Kiran; Ravindra K. Rawal; Sasanka Chakrabarti
Aim: A large body of evidence has implicated the cytotoxicity of α-synuclein in Parkinson's disease (PD). We planned to use a bioinformatics-based approach to gain further insight into this process. Materials & methods: Using STRING version 10, we identified interacting proteins of α-synuclein. Using α-synuclein and one of these interactors involved in apoptosis as query proteins, we identified other linked proteins. We further analyzed the interactions between some of these proteins by Protein-Protein Docking using ClusPro. Results: We identified BAX as an interacting protein of α-synuclein. Interactions of α-synuclein and BAX as well as BAX and BCL2L1 were determined. Conclusion: The interaction of α-synuclein and BAX could play a crucial role in the cell death process of PD where apoptosis and mitochondrial permeability transition-driven necrosis may coexist. © 2020 Sankha Shubhra Chakrabarti.
Iron Isomaltoside-Induced Anaphylaxis
(Lippincott Williams and Wilkins, 2022) Upinder Kaur; Amit Singh; Indrajeet S. Gambhir; Shubham Kashyap; Anup Singh; Sankha S. Chakrabarti
[No abstract available]
Isoniazid induced metabolic acidosis and renal dysfunction in an elderly patient with chronic renal disease
(Bentham Science Publishers B.V., 2016) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir
Metabolic acidosis is one of the common manifestations of Isoniazid toxicity but rare with normally used doses of the drug. Among anti tubercular drugs, rifampicin, streptomycin and capreomycin are commonly implicated in renal injury. Here we report the first case of metabolic acidosis and renal injury caused by isoniazid at normal prescribed dose. © 2016 Bentham Science Publishers.
Multi-Target Directed Ligands (MTDLs): Promising Coumarin Hybrids for Alzheimer’s Disease
(Bentham Science Publishers, 2021) Rohit Bhatia; Sankha S. Chakrabarti; Upinder Kaur; Gaurav Parashar; Anindita Banerjee; Ravindra K. Rawal
Alzheimer’s disease (AZD) is an age-associated neurodegenerative disorder and is one of the common health issues around the globe. It is characterized by memory loss and a decline in other cognitive domains, including executive function. The progression of AZD is associated with complex events, and the exact pathogenesis is still unrevealed. Various mechanisms which are thought to be associated with the initiation of AZD include a decreased concentration of acetylcholine (ACh), deposition of amyloid-β (Aβ) peptide, dyshomeostasis of redox metal ions, and prolonged oxidative stress. Due to the simultaneous progression of diverse pathogenetic pathways, no ideal therapeutic agent has been developed to date. The drugs which are available against AZD provide only symptomatic benefits and do not have disease-modifying activity. Therefore, in search of ideal therapeutic candidates, the concept of molecular hybrids has been under keen investigation for the past few years. Hybrid molecules are able to inhibit or activate or modify the physiology of more than one target simultaneously. Coumarin scaffold have shown the excellent potential of ACh esterase inhibition, MAO-B inhibition, and anti-Aβ aggregation. In the present review, we have focused on different reported coumarin hybrids as multi-target-directed agents against AZD. These include hybrids of coumarin with carbazole, benzofuran, dithiocarbamate, quinoline, pargyline, tacrine, N-benzyl pyridinium, donepezil, purine, piperidine, morpholine, aminophenol, benzylamino, halophenylalkylamidic, thiazole, thiourea, hydroxypyridinone, triazole, piperazine, chalcone, etc. Along with the therapeutic potentials of these hybrids, important clinical investigations and the structure-activity relationship have also been discussed in this compilation. © 2021 Bentham Science Publishers.
Newer insights in personalized and evidence based medicine- The role of microRNAs
(Bentham Science Publishers B.V., 2016) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir
Background: MicroRNAs are non-coding RNAs which regulate gene expression by binding to 3’ UTR site on mRNA. These small RNAs repress gene expression by interfering with the process of translation or by degrading the target mRNA. Abnormal expression of miRNAs has been implicated in a wide spectrum of human diseases like atherosclerosis, cancers and diabetes. Traditionally, pharmacogenomics focuses on single nucleotide polymorphisms and copy number variants of genes implicated in pharmacokinetics and pharmacodynamics. Recently, drug response has been proposed to be regulated by microRNAs. Mutations involving miRNAs can contribute to disease pathogenesis and modulation of drug response. Objective: The main objective of this review is to highlight the role of miRNAs in biological processes leading to disease states as well as in the field of drug action and pharmacogenomics. Method: A literature review was performed incorporating the latest insights in the field of miRNA therapeutics, diagnostics and pharmacogenomics. Results: Altered expression of miRNAs is seen in diabetes, vascular inflammation, atherosclerosis, infection and cancers. In the field of miRNA- pharmacogenomics, maximum work has been done studying the resistance to anticancer drugs. Some examples of microRNAs regulating drug response are miR-24 influencing the response to methotrexate, miR-125b affecting the action of calcitriol and miR-27b regulating the expression of CYP3A4. Among miRNAs currently being targeted in therapeutics are miR-122, miR- 33, miR-21, let-7 and miR-34. Conclusion: A significant fraction of all mRNAs transcribed in a cell are regulated by miRNAs. miRNAs implicated in a given disease may interfere with drug action and metabolism. Further research is needed to understand the association between miRNA, mRNAs, diseases and pharmacokinetics and dynamics. © 2017 Bentham Science Publishers.
Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India
(John Wiley and Sons Inc, 2022) Upinder Kaur; Sapna Bala; Bisweswar Ojha; Sumit Jaiswal; Sangeeta Kansal; Sankha S. Chakrabarti
The ChAdOx1 nCoV-19 vaccine (Oxford University-Astra Zeneca) has demonstrated nearly 70% efficacy against symptomatic COVID-19 in trials and some real-world studies. The vaccine was the first to be approved in India in early January 2021 and is manufactured by the Serum Institute of India. Favorable short-term safety data of the vaccine in India in a real-world setting has been recently demonstrated. Here, we report secondary objective (COVID-19 occurrence) measures of the same ongoing prospective observational study in prioritized recipients of the vaccine. The findings are based on participants who could complete at least 2 months of follow-up (n = 1500; female/male: 472/1028; mean age: 38.8 years). Laboratory confirmed SARS-CoV-2 infection was observed in 27/65 participants (41%) who received a single dose and 271/1435 (19%) who received both doses. Specifically, among doctors, 18/27 (66.7%) one dose recipients and 131/377 (34.7%) fully vaccinated developed SARS-CoV-2 infection. The majority of the cases were mild in all groups, and most were breakthrough infections. The occurrence of “severe” COVID-19 was 7.7 times lower (0.4%) in fully vaccinated participants compared to partially vaccinated (3.1%). Four deaths were observed in the study. One of the four deaths was due to sepsis, two due to unspecified cardiac events, and one due to unspecified post-COVID-19 complications. The results of this preliminary analysis necessitate vigorous research on the performance of vaccines against variants, optimal timing of vaccination, and also optimal timings of effectiveness studies to guide future vaccination policy. © 2021 Wiley Periodicals LLC
Refractory hypereosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine
(John Wiley and Sons Inc, 2022) Rohit Singh; Upinder Kaur; Ankur Singh; Sankha S. Chakrabarti
[No abstract available]